Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

Nagle, Advait and Biggart, Agnes and Be, Celine and Srinivas, Honnappa and Hein, Andreas and caridha, Diana and Sciotti, Richard and Pybus, Brandon and Kreishman-Deitrick, Mara and Bursulaya, Badry and Lai, Yin and Gao, Mu-Yun and Liang, Fang and Mathison, Casey and Liu, Xiaodong and Yeh, Vince and Smith, Jeffrey and Isabelle, Isabelle and Xie, Yongping and Chianelli, Donatella and Gibney, Michael and Berman, Ashley and Chen, Yen-Liang and Jiricek, Jan and Davis, Lauren and Liu, Xianzhong and Ballard, Jaime and Khare, Shilpi and Eggimann, Fabian and Luneau, Alexandre and Groessl, Todd and Shapiro, Michael and Richmond, Wendy and Johnson, Kevin and Rudewicz, Patrick and Rao, Srinivasa and Thompson, Christopher and Tuntland, Tove and Spraggon, Glen and Glynne, Richard and Supek, Frantisek and Wiesmann, Christian and Molteni, Valentina (2020) Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. Journal of Medicinal Chemistry. ISSN 0022-26231520-4804

Abstract

Visceral leishmaniasis is responsible for up to 30,000 deaths every year. Current treatments have shortcomings that include toxicity and variable efficacy across endemic regions. Previously, we reported the discovery of GNF6702, a selective inhibitor of the kinetoplastid proteasome, which cleared parasites in murine models of leishmaniasis, Chagas disease and human African trypamomiasis. Here, we describe the discovery and characterization of LXE408, a structurally related kinetoplastid-selective proteasome inhibitor currently in Phase 1 human clinical trials. In addition, we present high-resolution cryo-EM structures of the Leishmania tarentolae proteasome in complex with LXE408, which provides an explanation for the non-competitive mode of binding of this novel class of inhibitors to the kinetoplastid proteasome.

Item Type: Article
Date Deposited: 12 Aug 2020 00:45
Last Modified: 12 Aug 2020 00:45
URI: https://oak.novartis.com/id/eprint/42342

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.